David K Whynes1. 1. Nottingham FOB Screening Trial, School of Economics, University of Nottingham, Nottingham NG7 2RD, UK. david.whynes@nottingham.ac.uk
Abstract
OBJECTIVES: To estimate the cost-effectiveness of faecal occult blood (FOB) screening for colorectal cancer within the Nottingham trial. SETTING: A randomised controlled trial (1981-present) of 153,000 subjects, of whom approximately half were offered biennial FOB testing over up to five screening rounds. METHODS: The additional costs of participation in screening relative to symptomatic presentation were calculated by combining the results of (i) a comprehensive audit of resource use on the part of subjects within the trial, (ii) previously-established unit costs for each of the procedures involved. Life expectancy gains were estimated from a survival analysis of those trial subjects who had been diagnosed with cancer (screening participants vs controls). RESULTS: The cost of screening under the Nottingham trial protocol was pound 5290 per cancer detected (at 2002 prices). Under conservative assumptions, the incremental cost per life year gained as a result of screening was pound 1584 (Confidence Interval [CI]:717 to 8612).
RCT Entities:
OBJECTIVES: To estimate the cost-effectiveness of faecal occult blood (FOB) screening for colorectal cancer within the Nottingham trial. SETTING: A randomised controlled trial (1981-present) of 153,000 subjects, of whom approximately half were offered biennial FOB testing over up to five screening rounds. METHODS: The additional costs of participation in screening relative to symptomatic presentation were calculated by combining the results of (i) a comprehensive audit of resource use on the part of subjects within the trial, (ii) previously-established unit costs for each of the procedures involved. Life expectancy gains were estimated from a survival analysis of those trial subjects who had been diagnosed with cancer (screening participants vs controls). RESULTS: The cost of screening under the Nottingham trial protocol was pound 5290 per cancer detected (at 2002 prices). Under conservative assumptions, the incremental cost per life year gained as a result of screening was pound 1584 (Confidence Interval [CI]:717 to 8612).
Authors: Karen M Kuntz; Iris Lansdorp-Vogelaar; Carolyn M Rutter; Amy B Knudsen; Marjolein van Ballegooijen; James E Savarino; Eric J Feuer; Ann G Zauber Journal: Med Decis Making Date: 2011-06-14 Impact factor: 2.583
Authors: Bernard Denis; Marcel Ruetsch; Patrick Strentz; Jean Yves Vogel; Francis Guth; Jean Marc Boyaval; Xavier Pagnon; Jean François Ebelin; Isabelle Gendre; Philippe Perrin Journal: Gut Date: 2007-07-06 Impact factor: 23.059